NVIDIA and Eli Lilly Launch $1B AI Co-Innovation Lab to Reinvent Drug Discovery

oncodaily - Dave Ricks, Chair, CEO at Eli Lilly and Company, shared Eli Lilly and Company‘s post on LinkedIn, adding: “Exciting news from the JPMorgan Healthcare Conference: Lilly and NVIDIA are joining […]

AI Summary: Eli Lilly and Nvidia have teamed up to invest up to $1 billion in a brand‑new AI lab aimed at reinventing drug discovery. This collaborative venture promises to streamline R&D with cutting‑edge artificial intelligence while hinting that pharma’s reliance on tech is evolving – and it’s not all sci‑fi smoke and mirrors.

---

Warning: Undefined variable $thumbnail in /home3/thegood9/public_html/website_70aad9ea/cluster.php on line 61

Related Stories

---

Warning: Undefined variable $top_stories in /home3/thegood9/public_html/website_70aad9ea/cluster.php on line 128

Therapeutic HPV vaccine slows throat tumors in preclinical tests / 3 months

Gene‑editing trials explore one‑time fix for high cholesterol / 3 months

Bayer’s Asundexian Reduces Stroke Risk by 26% in Phase 3 Trial / 3 months

Eikon Therapeutics raises $381M IPO for cancer drug advancement / 3 months

Aktis Oncology IPO boosts radiopharmaceutical pipeline / 4 months

Tumor bacteria drive head and neck immunotherapy resistance / 4 months

Carolyn Bertozzi Returns to Eli Lilly Board / 5 months